Approximately 15 million women and girls of child-bearing age are living with epilepsy worldwide. To maintain optimal seizure control the majority of these women require treatment with antiseizure medications (ASMs) not only before conception but also throughout pregnancy and breastfeeding [1]. A growing body of evidence from observational studies and pregnancy registers has raised awareness regarding the potential teratogenic effects of ASMs [2]. The level of risk varies depending on the specific ASM.
14
ENE
ENE
0